Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
A Phase I Efficacy and Safety Study of HPV16-specific Therapeutic DNA-vaccinia Vaccination in Combination With Topical Imiquimod, in Patients With HPV16+ High Grade Cervical Dysplasia (CIN3)
Sponsor: National Cancer Institute (NCI)
A PHASE1 clinical study on Cervical Cancer and HPV Disease, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 13 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2022 — Sep 2023 [monthly]
Recruiting PHASE1
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jul 2020 [monthly]
Recruiting PHASE1
-
Nov 2018 — Dec 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .